Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224077 | 1.00 | ATM (0.48) | ATML3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL10896436 | 0.78 | MAPT (0.43) | ATML3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL11651390 | 0.78 | MAPT (0.43) | ATML3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL18820390 | 0.77 | GAA (0.42) | ATML3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL18820266 | 0.75 | GAA (0.41) | ATML3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL20042575 | 0.74 | NPC1 (0.48) | ATML3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL3231662 | 0.69 | DDB1 (0.42) | ATML3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL3231656 | 0.69 | DDB1 (0.42) | ATML3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL17053451 | 0.69 | ALDH1A1 (0.41) | ATML3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL18786507 | 0.67 | ALDH1A1 (0.45) | ATML3MBTL1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084569-B2 | Process for the synthesis of diaminopyridines from glutarimidines | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100056749-A1 | PROCESS FOR THE SYNTHESIS OF DIAMINOPYRIDINES FROM GLUTARIMIDINES | E. I. DU PONT DE NEMOURS AND COMPANY | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056749-A1 | PROCESS FOR THE SYNTHESIS OF DIAMINOPYRIDINES FROM GLUTARIMIDINES | DPYD, GCDH, OGDH | ATM 2169/4885L3MBTL1 4024/4885MAPT 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.